Chugai Pharmaceutical Co Ltd (CHGCY)
15.22
+0.32
(+2.15%)
USD |
OTCM |
May 31, 16:00
Chugai Pharmaceutical Enterprise Value: 45.03B for May 31, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 31, 2024 | 45.03B |
| May 30, 2024 | 43.98B |
| May 29, 2024 | 43.26B |
| May 28, 2024 | 44.54B |
| May 24, 2024 | 44.57B |
| May 23, 2024 | 44.38B |
| May 22, 2024 | 45.49B |
| May 21, 2024 | 47.60B |
| May 20, 2024 | 47.80B |
| May 17, 2024 | 47.60B |
| May 16, 2024 | 46.94B |
| May 15, 2024 | 46.42B |
| May 14, 2024 | 45.36B |
| May 13, 2024 | 46.75B |
| May 10, 2024 | 46.85B |
| May 09, 2024 | 47.30B |
| May 08, 2024 | 47.11B |
| May 07, 2024 | 47.60B |
| May 06, 2024 | 49.79B |
| May 03, 2024 | 49.64B |
| May 02, 2024 | 49.11B |
| May 01, 2024 | 47.17B |
| April 30, 2024 | 47.07B |
| April 29, 2024 | 46.45B |
| April 26, 2024 | 45.56B |
| Date | Value |
|---|---|
| April 25, 2024 | 46.25B |
| April 24, 2024 | 47.70B |
| April 23, 2024 | 50.20B |
| April 22, 2024 | 49.71B |
| April 19, 2024 | 47.24B |
| April 18, 2024 | 48.52B |
| April 17, 2024 | 48.75B |
| April 16, 2024 | 49.54B |
| April 15, 2024 | 48.56B |
| April 12, 2024 | 49.44B |
| April 11, 2024 | 51.24B |
| April 10, 2024 | 50.69B |
| April 09, 2024 | 53.23B |
| April 08, 2024 | 53.26B |
| April 05, 2024 | 54.15B |
| April 04, 2024 | 54.68B |
| April 03, 2024 | 55.66B |
| April 02, 2024 | 54.91B |
| April 01, 2024 | 56.75B |
| March 31, 2024 | 57.90B |
| March 28, 2024 | 57.71B |
| March 27, 2024 | 59.11B |
| March 26, 2024 | 59.26B |
| March 25, 2024 | 58.33B |
| March 22, 2024 | 58.30B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
33.29B
Minimum
Jun 12 2019
89.29B
Maximum
Jan 12 2021
52.06B
Average
49.81B
Median
Enterprise Value Benchmarks
| Takeda Pharmaceutical Co Ltd | 70.78B |
| Nxera Pharma Co Ltd | 932.97M |
| PeptiDream Inc | 1.615B |
| Healios KK | 57.40M |
| AnGes Inc | 59.01M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 501.30M |
| Revenue (Quarterly) | 1.597B |
| Total Expenses (Quarterly) | 923.59M |
| EPS Diluted (Quarterly) | 0.1523 |
| Gross Profit Margin (Quarterly) | 69.21% |
| Profit Margin (Quarterly) | 31.40% |
| Earnings Yield | 4.52% |
| Operating Earnings Yield | 6.10% |
| Normalized Earnings Yield | 4.516 |